Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Science and Technology Development Fund (STDF), ,Egypt | UNKNOWN |
Not provided
Not provided
Not provided
The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the mortality rate
To test the efficacy of IL-2 inhibitors (Cyclosporine) compared to the Standard of care according to hospital protocol on COVID-19 patients concerning the clinical outcome (cytokines level, clinical improvement, and PCR of SARS-CoV-2 through the study period).
AIM:
The slow progression of the disease, improving survival among COVID-19 patients, and Standard assessment of patient improvement.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| cyclosporine | Experimental | patients will receive cyclosporine + (standard care treatment (± anticoagulant± antibiotic± antipyretic± steroid) according to Alexandria university hospitals protocol ) |
|
| Standard of care treatment | Active Comparator | patients will receive standard treatment (antiviral ± anticoagulant± antibiotic± antipyretic± steroid± interleukin ) according to Alexandria university hospitals protocol. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| cyclosporine | Drug | Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of subjects with a 6-point ordinal scale showing each severity level | i. Death ii. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation iii. Hospitalized, on non-invasive ventilation or high flow oxygen devices iv. Hospitalized, requiring supplemental oxygen v. Hospitalized, not requiring supplemental oxygen vi. Not hospitalized | 7-14 days after randomization |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of hospital admission | efficacy of CsA (cyclosporine) in reducing days in hospital | through study completion, an average of 4 weeks |
| Rate of decline OF Soluble interleukin-2 (IL-2) receptor alpha. (sCD25) |
Not provided
Inclusion Criteria:
Current infection with COVID-19
written informed consent
Confirmed diagnosis of COVID-19 by PCR (polymerase chain reaction) tests and/or Positive Serology or any existing and validated diagnostic COVID-19 parameters during this time.
18yrs ≥ Age <66 yrs
Chest X-ray showing suggestive of COVID-19 disease.
Both gender
The presence of Pulmonary fibrosis or hyper inflammation signs or A syndrome of cytokine release defined as any of the following::
Exclusion Criteria:
Lactation and Pregnancy women
unlikely to survive beyond 48h
Need for mechanical ventilation.
cases of multiorgan failure or abnormal renal function and shock.
malignancies, autoimmune disease, Perforation of the bowels or diverticulitis.
active bacterial or fungal infection.
We define impairment of cardiac function as poorly controlled heart diseases, cardiac insufficiency, unstable angina pectoris, myocardial infarction within 1 year before enrollment, supraventricular or ventricular arrhythmia needs treatment or intervention, Uncontrolled hypertension (>180/110 mmHg.
Levels of serum transaminase >5 upper references rang
Symptoms of active tuberculosis or human immunodeficiency virus (HIV) positivity
the patient receiving Vaccines: Live, attenuated vaccines
Subjects received monoclonal antibodies within one week before admission.
Patients receiving high-dose systemic steroids (> 20 mg methylprednisolone or equivalent), immunosuppressant or immunomodulatory drugs
Contraindications for use in people with psoriasis include concomitant treatment with methotrexate, other immunosuppressant agents, coal tar, or radiation therapy.
-
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Maged El-Setouhy | Alexandria University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Alexandria university | Alexandria | 21523 | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31446206 | Background | Fellman CL, Archer TM, Wills RW, Mackin AJ. Effects of cyclosporine and dexamethasone on canine T cell expression of interleukin-2 and interferon-gamma. Vet Immunol Immunopathol. 2019 Oct;216:109892. doi: 10.1016/j.vetimm.2019.109892. Epub 2019 Jul 11. | |
| 8129618 | Background | Damaso CR, Keller SJ. Cyclosporin A inhibits vaccinia virus replication in vitro. Arch Virol. 1994;134(3-4):303-19. doi: 10.1007/BF01310569. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
change from baseline in IL-2 levels
| Days 1, 8, 15 or at hospital discharge(through study completion, an average of 6 weeks) |
| Rate of decline OF interleukin-1 | change from baseline in IL-1 levels | Days 1, 8, 15 or at hospital discharge(through study completion, an average of 6 weeks) |
| Rate of decline OF interleukin-10(IL-10) | change from baseline in IL-10 levels | Days 1, 8, 15 or at hospital discharge(through study completion, an average of 4 weeks) |
| Rate of decline OF Interleukin-6,( IL-6) | change from baseline in IL-6levels | Days 1, 8, 15 or at hospital discharge(through study completion, an average of 4 weeks) |
| Rate of decline OF Tumour necrosis factor α (TNFα) | change from baseline in TNFα levels | Days 1, 8, 15 or at hospital discharge(through study completion, an average of 4 weeks) |
| Time to 50% a decrease of ferritin levels compared to peak value during trial | change from baseline in ferritin levels | up to 28 days |
| Lung imaging improvement time | COVID19 Lung imaging determination | up to 28 days |
| Time for non-invasive or invasive initial use | efficacy of CSA in reducing days of ventilators | during hospital admission (up to 28 days)] |
| Time to improvement in oxygenation | defined as independence from supplemental oxygen | up to 28 days) from hospitalization |
| Number of days safe from ventilators | efficacy of CSA in reducing days of ventilators | during hospital admission (up to 28 days) |
| Number of days on mechanical ventilation | to evaluate the efficacy of CSA in reducing days of ventilators | during hospital admission (up to 28 days) |
| Number of days in the intensive care unit after randomization | to evaluate the efficacy of CSA in reducing days in the intensive care unit | during hospital admission (up to 28 days)] |
| Incidence of (Adverse Events) and Incidence of nosocomial bacterial or invasive fungal infection | to evaluate the safety of CSA | during hospital admission (up to 28 days)] |
| Mean change of SOFA score in ICU patients | The Sequential Organ Failure Assessment (SOFA) score: 0 (best) - 24 (worse) The SOFA score will be used to assess the probability of organ failure and mortality in ICU patients | between 1, 15 days) hospital discharge |
| Mean improvement in Clinical Deterioration Changed Early Warning Score (MEWS) between 1, 15 days) | efficacy of CsA in Clinical improvement | between 1, 15 days) hospital discharge |
| rate of Mortality | efficacy of CsA in reducing mortality | throughout 30 and 90 days |
| all-cause mortality will be measured. | efficacy of CsA in reducing mortality | At 28, 30, and 90 days, |
| 19821520 | Background | Ciesek S, Steinmann E, Wedemeyer H, Manns MP, Neyts J, Tautz N, Madan V, Bartenschlager R, von Hahn T, Pietschmann T. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology. 2009 Nov;50(5):1638-45. doi: 10.1002/hep.23281. |
| ID | Term |
|---|---|
| D000080424 | Cytokine Release Syndrome |
| D011658 | Pulmonary Fibrosis |
| D000086382 | COVID-19 |
| D012128 | Respiratory Distress Syndrome |
| ID | Term |
|---|---|
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |
| D017563 | Lung Diseases, Interstitial |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D005355 | Fibrosis |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D012120 | Respiration Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D016572 | Cyclosporine |
| D007376 | Interleukin-2 |
| ID | Term |
|---|---|
| D003524 | Cyclosporins |
| D010456 | Peptides, Cyclic |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D007378 | Interleukins |
| D016207 | Cytokines |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D008222 | Lymphokines |
| D011506 | Proteins |
| D001685 | Biological Factors |
Not provided
Not provided